Aptinyx Inc. (NASDAQ:APTX) Short Interest Update

Aptinyx Inc. (NASDAQ:APTXGet Rating) was the recipient of a large drop in short interest in the month of December. As of December 30th, there was short interest totalling 92,900 shares, a drop of 67.0% from the December 15th total of 281,200 shares. Currently, 0.2% of the company’s stock are sold short. Based on an average daily trading volume, of 267,900 shares, the short-interest ratio is currently 0.3 days.

Aptinyx Stock Performance

Shares of APTX stock opened at $0.49 on Wednesday. The company has a debt-to-equity ratio of 0.51, a quick ratio of 27.45 and a current ratio of 27.45. The company has a market capitalization of $33.25 million, a P/E ratio of -0.46 and a beta of 1.05. The company’s 50 day moving average price is $0.31 and its two-hundred day moving average price is $0.40. Aptinyx has a 52 week low of $0.20 and a 52 week high of $3.76.

Aptinyx (NASDAQ:APTXGet Rating) last announced its earnings results on Tuesday, November 8th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.01. On average, analysts expect that Aptinyx will post -0.97 earnings per share for the current fiscal year.

Institutional Trading of Aptinyx

Hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in shares of Aptinyx by 8.4% in the first quarter. Vanguard Group Inc. now owns 1,964,058 shares of the company’s stock valued at $4,459,000 after purchasing an additional 152,943 shares during the last quarter. Millennium Management LLC raised its holdings in shares of Aptinyx by 11.0% in the second quarter. Millennium Management LLC now owns 1,516,726 shares of the company’s stock valued at $846,000 after purchasing an additional 150,250 shares during the last quarter. Northern Trust Corp raised its holdings in shares of Aptinyx by 203.7% in the first quarter. Northern Trust Corp now owns 219,698 shares of the company’s stock valued at $498,000 after purchasing an additional 147,357 shares during the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Aptinyx by 13.5% in the first quarter. Dimensional Fund Advisors LP now owns 140,711 shares of the company’s stock valued at $320,000 after purchasing an additional 16,774 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Aptinyx by 116.4% in the second quarter. Renaissance Technologies LLC now owns 568,914 shares of the company’s stock valued at $317,000 after purchasing an additional 305,988 shares during the last quarter. 45.93% of the stock is currently owned by institutional investors and hedge funds.

Aptinyx Company Profile

(Get Rating)

Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia.

Featured Articles

Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.